Chance of response to an antidepressant: what should we say to the patient?

Steinert, Tilman

doi:10.1002/wps.20511

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…E.g., can full disclosure of diagnoses (e.g., schizophrenia, personality disorder) lead to stigmatization? Should patients be told about limited treatment expectations (e.g., regarding antidepressants), or does this conflict with the physician's duty to offer hope ( 2 ) A question that is of relevance in medicine in general, does perfect information disclosure annihilate any positive placebo effect that contribute considerably to positive outcomes? On the other hand, insufficient information and education can limit a patient's competence to deal with their condition and lead to non-adherence with treatment.…”

Section: Patient Information and Informed Consentmentioning

confidence: 99%

Law and psychiatry—current and future perspectives

Steinert

Henking

2022

Front. Public Health

Self Cite

View full text Add to dashboard Cite

We describe relevant interfaces between law and psychiatry and current ethical and legal views and changes within the past decades. Ideas of patient autonomy and patients' rights have been major drivers of changes in legal frameworks. We describe developments in the areas of patient information and informed consent, involuntary placement and involuntary treatment, use of coercive measures, forensic psychiatry, digital mental health, data privacy, physician liability, suicide, assisted suicide, euthanasia, end of life decision-making, advance directives, legal and illegal drugs, and delegation and substitution of professional activities. There is no unidirectional pathway between law and ethics. Views, conflicts, and requirements differ between countries and within countries and will need to be balanced according to the societies' changing values also in the future.

show abstract

Section: Patient Information and Informed Consentmentioning

confidence: 99%

Law and psychiatry—current and future perspectives

Steinert

Henking

2022

Front. Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…According to a recent review (40), treatment of PD depends on symptom severity and functional impairment (41, 42). Cognitive behavioral therapy (43), interpersonal psychotherapy, and psychoeducation (44, 45) are usually adopted in case of mild to moderate forms of PD; while antidepressants, more often selective serotonin reuptake inhibitors (SSRI), are used for severe cases (46–51).…”

Section: Introductionmentioning

confidence: 99%

Psychoeducational Intervention for Perinatal Depression: Study Protocol of a Randomized Controlled Trial

et al. 2019

View full text Add to dashboard Cite

Perinatal depression (PD) is a severe and disabling condition impacting negatively on children in terms of adverse neonatal outcomes and on the well-being of women and their families. All pregnant women attending the unit of Gynecology and Obstetrics Service of the University of Campania “L. Vanvitelli” will be screened for PD using the Edinburgh Postpartum Depression Scale (EPDS). Women with a score ≥10 at the EPDS will be invited to receive a full psychiatric assessment. The required sample size is of 126 women with PD which will be randomly allocated to either an experimental group, receiving a uni-familiar psychoeducational intervention, or to a control group, receiving the Best Treatment Option (BTO). Patients will be evaluated through several assessment instruments: Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A), Global Assessment of Functioning (GAF), Clinical Global Impression (CGI), Manchester Short Assessment of Quality of Life (MANSA), Family Assessment Device (FAD), Family Coping Questionnaire (FCQ), and Pattern of Care Schedule (PCS). Patients will be evaluated at baseline, 3, 6, 9, and 12 months post-randomization. The severity of depressive symptoms at the HAM-D scale has been selected as primary outcome. Other outcome measures include improvement in the severity of anxiety symptoms, of global and personal functioning, an improvement in family members' coping strategies and in the level of quality of life. It has been highlighted the importance of developing screening and treating programs for PD, and our study will use rigorous study design to evaluate the efficacy of the adaption of a well-known family psychoeducational model to the treatment of PD. The aims of present trial are to: (1) develop an informative package for pregnant women with PD; (2) promote a screening programme for PD; (3) identify those (socio-demographic and pregnancy-related environmental) factors associated with a higher risk to develop a perinatal or postnatal depression; (4) evaluate the efficacy of a new experimental psychoeducational intervention in reducing the depressive symptoms during pregnancy compared to the BTO.

show abstract